Literature DB >> 16716778

Hybrid spectrin type repeats produced by exon-skipping in dystrophin.

Nick Menhart1.   

Abstract

Dystrophin is the protein whose defect underlies Duchenne Muscular Dystrophy, DMD, a common (1:3500 male births) and fatal condition in which muscle tissue deteriorates leading to death in the second or third decade of life. Dystrophin is coded for by the largest human gene, and one of the most complex. It is translated from at least 7 distinct promoters, with the largest transcripts (which are the ones involved in DMD) containing 79 exons over >2.5 Mbp [K.F. O'Brien, L.M. Kunkel, Dystrophin and muscular dystrophy: past, present, and future, Mol. Genet. Metab. 74 (2001) 75-88, H.M. Sadoulet-Puccio, L.M. Kunkel, Dystrophin and its isoforms, Brain Pathol. 6 (1996) 25-35]. Exacerbating this complexity, it has recently been shown that dystrophin is subject to extensive alternative RNA processing, potentially producing a wide variety dystrophin variants [M. Sironi, R. Cagliani, U. Pozzoli, A. Bardoni, G.P. Comi, R. Giorda, N. Bresolin, The dystrophin gene is alternatively spliced throughout its coding sequence FEBS Lett 517 (2002) 163-166]. The structure of the dystrophin protein is highly modular, with the most common module being a motif termed the spectrin type repeat, or STR, of which there are 24. Each STR is roughly coded for by two exons, and the most common type of multiple exon-skipping events start and end at introns in the middle of STRs [R.G. Roberts, A.J. Coffey, M. Bobrow, D.R. Bentley, Exon structure of the human dystrophin gene Genomics 16 (1993) 536-538, M. Koenig, L.M. Kunkel, Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility, J. Biol. Chem. 265 (1990) 4560-4566]. This would produce fractional STR modules, however, the concept of STRs as proteins domains makes the viability of such fractional motifs questionable. However, certain of these events produce pairs of potentially complementary fractional domain that might reassemble into a hybrid STR motif. We have constructed model fragment corresponding to one such exon-skipping event, and show that the hybrid STR so produced is viable, and furthermore that some of the properties of the protein containing it differ substantially of the native, un-skipped parent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716778      PMCID: PMC1925050          DOI: 10.1016/j.bbapap.2006.03.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  44 in total

1.  The dystrophin gene is alternatively spliced throughout its coding sequence.

Authors:  M Sironi; R Cagliani; U Pozzoli; A Bardoni; G P Comi; R Giorda; N Bresolin
Journal:  FEBS Lett       Date:  2002-04-24       Impact factor: 4.124

Review 2.  Splicing intervention for Duchenne muscular dystrophy.

Authors:  Graham McClorey; Susan Fletcher; Stephen Wilton
Journal:  Curr Opin Pharmacol       Date:  2005-10       Impact factor: 5.547

3.  Analysis of splicing parameters in the dystrophin gene: relevance for physiological and pathogenetic splicing mechanisms.

Authors:  M Sironi; U Pozzoli; R Cagliani; G P Comi; A Bardoni; N Bresolin
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

4.  Crystal structure of the alpha-actinin rod reveals an extensive torsional twist.

Authors:  J Ylänne; K Scheffzek; P Young; M Saraste
Journal:  Structure       Date:  2001-07-03       Impact factor: 5.006

Review 5.  Dystrophin and muscular dystrophy: past, present, and future.

Authors:  K F O'Brien; L M Kunkel
Journal:  Mol Genet Metab       Date:  2001 Sep-Oct       Impact factor: 4.797

6.  Signatures of domain shuffling in the human genome.

Authors:  Henrik Kaessmann; Sebastian Zöllner; Anton Nekrutenko; Wen-Hsiung Li
Journal:  Genome Res       Date:  2002-11       Impact factor: 9.043

Review 7.  Brain dystrophin, neurogenetics and mental retardation.

Authors:  M F Mehler
Journal:  Brain Res Brain Res Rev       Date:  2000-04

8.  Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Authors:  Scott Q Harper; Michael A Hauser; Christiana DelloRusso; Dongsheng Duan; Robert W Crawford; Stephanie F Phelps; Hollie A Harper; Ann S Robinson; John F Engelhardt; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 9.  Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin.

Authors:  Jeannine M Scott; Sheng Li; Scott Q Harper; Robert Welikson; Daniel Bourque; Christiana DelloRusso; Stephen D Hauschka; Jeffrey S Chamberlain
Journal:  Neuromuscul Disord       Date:  2002-10       Impact factor: 4.296

10.  Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable.

Authors:  Scott Q Harper; Robert W Crawford; Christiana DelloRusso; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2002-08-01       Impact factor: 6.150

View more
  13 in total

1.  Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation.

Authors:  Davin M Henderson; Ann Lee; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  IRBIS: a systematic search for conserved complementarity.

Authors:  Dmitri D Pervouchine
Journal:  RNA       Date:  2014-08-20       Impact factor: 4.942

3.  Differential stabilities of alternative exon-skipped rod motifs of dystrophin.

Authors:  Chris Ruszczak; Ahmed Mirza; Nick Menhart
Journal:  Biochim Biophys Acta       Date:  2009-03-12

4.  Stability of dystrophin STR fragments in relation to junction helicity.

Authors:  Ahmed Mirza; Nick Menhart
Journal:  Biochim Biophys Acta       Date:  2008-06-06

5.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

Authors:  Yi Lai; Gail D Thomas; Yongping Yue; Hsiao T Yang; Dejia Li; Chun Long; Luke Judge; Brian Bostick; Jeffrey S Chamberlain; Ronald L Terjung; Dongsheng Duan
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

Review 6.  A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.

Authors:  Toshifumi Yokota; Shin'ichi Takeda; Qi-Long Lu; Terence A Partridge; Akinori Nakamura; Eric P Hoffman
Journal:  Arch Neurol       Date:  2009-01

Review 7.  Optimizing exon skipping therapies for DMD.

Authors:  T Yokota; W Duddy; T Partridge
Journal:  Acta Myol       Date:  2007-12

8.  Multiple exon skipping strategies to by-pass dystrophin mutations.

Authors:  Carl F Adkin; Penelope L Meloni; Susan Fletcher; Abbie M Adams; Francesco Muntoni; Brenda Wong; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2011-12-17       Impact factor: 4.296

9.  Computational study of the human dystrophin repeats: interaction properties and molecular dynamics.

Authors:  Baptiste Legrand; Emmanuel Giudice; Aurélie Nicolas; Olivier Delalande; Elisabeth Le Rumeur
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

10.  The crystal structures of dystrophin and utrophin spectrin repeats: implications for domain boundaries.

Authors:  Muralidharan Muthu; Kylie A Richardson; Andrew J Sutherland-Smith
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.